Fibromyalgia syndrome module at OMERACT 9: Domain construct

Journal of Rheumatology

Volumn 36, Issue 10, 2009, Pages 2318-2329

  Mease, Philip ^a   Arnold, Lesley M ^b   Choy, Ernest H ^c   Clauw, Daniel J ^d   Crofford, Leslie J ^e   Glass, Jennifer M ^d   Martin, Susan A ^f   Morea, Jessica ^g   Simon, Lee ^h   Strand, C Vibeke ⁱ   Williams, David A ^d  

^a SWEDISH MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF MICHIGAN   (United States)

^e UNIVERSITY OF KENTUCKY   (United States)

^f RTI HEALTH SOLUTIONS   (United States)

^g OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^h BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

ⁱ STANFORD UNIVERSITY   (United States)

Author keywords

Clinical trials; Fibromyalgia; Omeract; Outcome measures

Indexed keywords

BIOLOGICAL MARKER;

ANXIETY; CEREBROSPINAL FLUID; CLINICAL ASSESSMENT; CLINICAL PRACTICE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONFERENCE PAPER; CONSENSUS; DEPRESSION; FATIGUE; FIBROMYALGIA; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; MUSCLE STIFFNESS; OUTCOME ASSESSMENT; PAIN; PERFORMANCE MEASUREMENT SYSTEM; PRIORITY JOURNAL; QUALITY OF LIFE; SELF EVALUATION; SELF REPORT; SLEEP DISORDER;

CLINICAL TRIALS AS TOPIC; DELPHI TECHNIQUE; FIBROMYALGIA; HUMANS; INTERNATIONAL COOPERATION; OUTCOME ASSESSMENT (HEALTH CARE); SYNDROME;

EID: 70450177636     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.090367     Document Type: Conference Paper

References (59)

1. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: Report of the multicenter criteria committee. Arthritis Rheum 1990;33:160-172
2. Mease P. Fibromyalgia syndrome: Review of clinical presentation, pathogenesis, outcome measures, and treatment. J Rheumatol 2005;32:6-21. (Pubitemid 41113954)
3. Staud R. The neurobiology of chronic musculoskeletal pain (including chronic regional pain). In: Wallace DJ, Clauw DJ, editors. Fibromyalgia and other central pain syndromes. Philadelphia: Lippincott Williams & Wilkins;2005:45-62.
4. Clauw DJ. Fibromyalgia: Update on mechanisms and management. J Clin Rheum 2007;13:102-109
5. Bennett RM, Jones J, Turk DC, Russell IJ, Matallana L. An internet survey of 2,596 people with fibromyalgia. BMC Musculoskel Disorders 2007;9:27-38.
6. Moldofsky H, Scarisbrick P, England R, Smythe HA. Musculoskeletal symptoms and non-REM sleep disturbance in patients with "fibrositis syndrome" and healthy subjects. Psychosom Med 1975;37:341-345
7. Arnold LM, Keck Jr PE, Welge JA. Antidepressant treatment of fibromyalgia. A meta-analysis and review. Psychosomatics 2000;41:104-113
8. Mease PJ, Russell IJ, Arnold LM, et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol 2008;35:502-514
9. Arnold LM, Russell IJ, Diri EW, et al. A 14-week, randomised, double-blind, placebo-controlled monotherapy trial of pregabalin for pain in patients with fibromyalgia. J Pain 2008;9:792-805.
10. Russell IJ, Mease PJ, Smith TR, et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomised, double-blind, placebo-controlled, fixed-dose trial. Pain 2008;136:432-444
11. Mease PJ, Clauw DJ, Gendreau RM, Rao SG, Kranzler J, Chen W, Palmer RH. The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial. J Rheumatol 2009;36:398-409.
12. Clauw DJ, Mease P, Palmer RH, Gendreau RM, Wang Y. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther 2008;30:1988-2004.
13. Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia impact questionnaire: development and validation. J Rheumatol 1991;18:728-733
14. Mease PJ, Clauw DJ, Arnold LM, et al. Fibromyalgia syndrome. J Rheumatol 2005;32:2270-2277
15. Mease P, Arnold LM, Bennett R, et al. Fibromyalgia syndrome. J Rheumatol 2007;34:1415-1452
16. Arnold LM, Crofford LJ, Mease PJ, et al. Patient perspectives on the impact of fibromyalgia. Patient Edu Couns 2008, Epub.
17. Mease PJ, Arnold LM, Crofford LJ, et al. Identifying the clinical domains of fibromyalgia: Contributions from clinical and patients delphi exercises. Arthritis Care Res 2008;59:952-960
18. Dadabhoy D, Crofford LJ, Spaeth M, Russell IJ, Clauw DJ. Evidence-based biomarkers for fibromyalgia syndrome. Arthritis Res Ther 2008;10:211.
19. Choy EH, Arnold LM, Clauw D, et al. Content and criterion validity of the preliminary core dataset for clinical trials in fibromyalgia syndrome. J Rheumatol 2009;36:xxxx.
20. Ware J, Kosinski M, Dewey J. How to score version 2 of the SF-36 health survey standard and acute forms. Lincoln: Quality Metric; 2000.
21. Ware JE, Kosinski M. Interpreting SF-36 summary health measures: a response. Qual Life Res 2001;10:405-413 (Pubitemid 33081995)
22. Ware J, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996;34:220-233 (Pubitemid 126433231)
23. Hoffman DL, Dukes EM. The health status burden of people with fibromyalgia: a review of studies that assessed health status with the SF-36 or the SF-12. Int J Clin Pract 2008;62:115-126
24. Arnold LM, Pritchett YL, D'Souza DN, Kajdasz DK, Iyengar S, Wernicke JF. Duloxetine for the treatment of fibromyalgia in women: pooled results from two randomised, placebo-controlled clinical trials. J Womens Health 2007;16:1145-1156 (Pubitemid 47587341)
25. Arnold LM, Goldenberg D, Stanford SB, Lalonde JK, Sandhu HS, Keck PE. Gabapentin in the treatment of fibromyalgia: a randomised, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum 2007;56:1336-1344 (Pubitemid 46608659)
26. Strand V, Williams DA, Gendreau M, Palmer RH. Improvement in health related quality of life and multidimensional function with milnacipran treatment in fibromyalgia. 2008 (in progress).
27. Simms RW, Felson DT, Goldenberg DL. Development of preliminary criteria for response to treatment in fibromyalgia syndrome. J Rheumatol 1991;18:1558-1563
28. Simms RW, Felson DT, Goldenberg DL. Criteria for response to treatment in fibromyalgia [abstract]. Arthritis Rheum 1998;31:S100.
29. Carette S, Bell MJ, Reynolds WJ, et al. Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia. A randomised, double blind clinical trial. Arthritis Rheum 1994;37:32-40.
30. Dunkl PR, Taylor AG, McConnell GG, Alfano AP, Conaway MR. Responsiveness of fibromyalgia clinical trial outcome measures. J Rheumatol 2000;27:2683-2691 (Pubitemid 30847948)
31. Russell IJ, Perkins AT, Michalek JE. Sodium oxybate relieves pain and improves function in fibromyalgia syndrome: a randomized, double-blind, placebo-controlled, multicenter clinical trial. J Rheumatol 2009;60:299-309.
32. World Health Organization, International classification of functioning, disability, and health. Geneva:WHO; 2001.
33. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995;38:19-28.
34. Croft P, Rigby AS, Boswell R, Schollum J, Silman A. The prevalence of chronic widespread pain in the general population. J Rheumatol 1993;20:710-713. (Pubitemid 23138864)
35. Coster L, Kendall S, Gerdle B, Henriksson C, Henriksson KG, Bengtsson A. Chronic widespread musculoskeletal pain - a comparison of those who meet criteria for fibromyalgia and those who do not. Eur J Pain 2008;12:600-610 (Pubitemid 351618415)
36. Offenbaecher M, Cieza A, Brockow T, et al. Are the contents of treatment outcomes in fibromyalgia trials represented in the International Classification of Functioning, Disability and Health? Clin J Pain 2007;23:691-701. (Pubitemid 47462176)
37. Prodinger B, Cieza A, Williams DA, et al. Measuring health in patients with fibromyalgia: content comparison of questionnaires based on the International Classification of Functioning, Disability and Health. Arthritis Rheum 2008;59:650-658 (Pubitemid 351679539)
38. Williams DA. A fibromyalgia specific extension of the PROMIS network. 2008, Presented at the Second PROMIS Conference: Improving measurement of patient reported outcomes - new tools and the science behind them. Bethesda, Maryland, 2008.
39. Fries J, Bruce B, Cella D. The promise of PROMIS: using item response theory to improve assessment of patient-reported outcomes. Clin Exp Rheumatol 2005;23:S53-7. (Pubitemid 46657511)
40. US Department of Health and Human Services. Food and Drug Administration. CDER2002193, docket no. 2006D-0044. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims draft guidance. Health Qual Life Outcomes 2006;4:79.
41. Geisser ME, Gracely RH, Giesecke T, Petzke F, Williams DA, Clauw DJ. The association between experimental and clinical pain measures among persons with fibromyalgia and chronic fatigue syndrome. Eur J Pain 2007;11:202-207 (Pubitemid 44820896)
42. Harris RE, Gracely RH, McLean SA, et al. Comparison of clinical and evoked pain measures in fibromyalgia. J Pain 2006;7:521-527 (Pubitemid 43929434)
43. Petzke F, Clauw DJ, Ambrose K, Khine A, Gracely RH. Increased pain sensitivity in fibromyalgia: effects of stimulus type and mode of presentation. Pain 2003;105:403-413 (Pubitemid 37186903)
44. Petzke F, Gracely RH, Park KM, Ambrose K, Clauw DJ. What do tender points measure? Influence of distress on 4 measures of tenderness. J Rheumatol 2003;30:567-574 (Pubitemid 36301951)
45. Gracely RH, Grant MA, Giesecke T. Evoked pain measures in fibromyalgia. Best Pract Res Clin Rheumatol 2003;17:593-609.
46. Wolfe F. The relation between tender points and fibromyalgia symptom variables: evidence that fibromyalgia is not a discrete disorder in the clinic. Ann Rheum Dis 1997;56:268-271 (Pubitemid 27239584)
47. Katz RS, Heard AR, Mills M, Leavitt F. The prevalence and clinical impact of reported cognitive difficulties (Fibrofog) in patients with rheumatic diseases with and without fibromyalgia. J Clin Rheumatol 2004;10:53-58 (Pubitemid 38496092)
48. Zachrisson O, Regland B, Jahreskog M, Kron M, Gottfries CG. A rating scale for fibromyalgia and chronic fatigue syndrome (the FibroFatigue scale). J Psychosom Res 2002;52:501-509 (Pubitemid 34759879)
49. Glass JM. Cognitive dysfunction in fibromyalgia and chronic fatigue syndrome: new trends and future directions. Curr Rheumatol Rep 2006;8:425-429
50. Sletvold H, Stiles TC, Landro NI. Information processing in primary fibromyalgia, major depression and healthy controls. J Rheumatol 1995; 22:137-142
51. Grace GM, Nielsen WR, Hopkins M, Berg MA. Concentration and memory deficits in patients with fibromyalgia syndrome. J Clin Exp Neuropsychol 1999;21:477-487
52. Leavitt F, Katz RS. Distraction as a key determinant of impaired memory in patients with fibromyalgia. J Rheumatol 2006;33:127-132 (Pubitemid 43054292)
53. Park DC, Glass JM, Minear M, Crofford LJ. Cognitive function in fibromyalgia patients. Arthritis Rhuem 2001;44:2125-2133
54. Dick B, Eccleston C, Crombez G. Attentional functioning in fibromyalgia, rheumatoid arthritis, and musculoskeletal pain patients. Arthritis Rheum 2002;47:639-644 (Pubitemid 35461317)
55. Glass JM, Park DC, Minear M, Crofford LJ. Memory beliefs and function in fibromyalgia patients. J Psychosom Res 2005;58:263-269 (Pubitemid 40603914)
56. Cote KA, Moldofsky H. Sleep, daytime symptoms, and cognitive performance in patients with fibromyalgia. J Rheumatol 1997;24:2014-2023 (Pubitemid 27431937)
57. Landro NI, Stiles TC, Sletvold H. Memory functioning in patients with primary fibromyalgia and major depression and healthy controls. J Psychosom Res 1997;42:297-306. (Pubitemid 27186881)
58. Grisart J, van der Linden M, Masquelier E. Controlled processes and automaticity in memory functioning in fibromyalgia patients: relation with emotional distress and hypervigilance. J Clin Exp Neuropsychol 2002;24:994-1009. (Pubitemid 36605529)
59. Walitt B, Roebuck-Spencer T, Bleiberg J, Weinstein A. Automated neuropsychiatric measurements of information processing in fibromyalgia. Rheumatol Int 2008;28:561-566